— Up to 8 winners to receive up to $500,000 each in pre-seed funding, incubator space, equity for discovery services, and expert mentorship— CAMBRIDGE, Mass., April 7, 2025— Mission BioCapital (MBC), in partnership with sponsors Eli Lilly and Company (Lilly), Ono Venture Investment (OVI), Alloy Therapeutics, and our newest sponsor, HitGen, announced today that applications
Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter program has the potential to reset the immune system Acquisition underpins path for Sanofi becoming leading immunology company Sanofi to pay $600 million up front Paris, March 20, 2025. – Sanofi and Dren Bio,
CAMBRIDGE, Mass., February 5, 2025 — We are proud to announce today that we have promoted three Mission BioCapital (MBC) investment professionals and extended our capabilities by adding three new team members. “In recognition of their contributions and value to our team, we are so pleased to have promoted Cassidy Blundell and Zach Collins to
Mission BioCapital Announces Team Promotions and New Hires Read More »
— Pilot & first-year Platinum Program has provided eight companies pre-seed funding totaling $3.5 million, lab space, and mentorship and is now offering drug discovery and corporate advisory services from new sponsors Alloy Therapeutics, Goodwin, and van den Boom & Associates — CAMBRIDGE, Mass., October 30, 2024— Mission BioCapital (MBC) announced today the first eight
— Up to 6 winners are eligible for up to $3 million in seed funding, incubator space, $1 million in total equity for discovery services from Alloy Therapeutics, and expert mentorship — CAMBRIDGE, Mass., May 1, 2024— Mission BioCapital (MBC), in partnership with founding sponsors Eli Lilly and Company (Lilly) and Ono Venture Investment (OVI)
— Following success of 2022 pilot, MBC boosts 2023 program with substantially increased funding, geographic reach, and scientific expertise — — Applications now open — CAMBRIDGE, Mass., June 12, 2023—— Mission BioCapital (MBC) announced today the launch of the Mission BioCapital Platinum Program 2023 to identify and support high-potential life sciences startup companies. In collaboration
Underrepresented biotech founders developing novel health solutions will gain access to LabCentral’s lab space, resources and community CAMBRIDGE, Mass., Oct. 5, 2022— LabCentral Ignite, with support from key sponsors Pfizer, Bristol Myers Squibb and Mission BioCapital, today announced the winners of its second annual Golden Ticket contest: Cellens, Guardian Bio, QurCan Therapeutics and Spheric Bio.
Offers opportunity for underrepresented biotech entrepreneurs to benefit from LabCentral’s lab space, shared resources and community CAMBRIDGE, Mass., June 21, 2022— LabCentral, with support from Pfizer, Bristol Myers Squibb (BMS) and Mission BioCapital, today announced the launch of its second annual LabCentral Ignite Golden Ticket contest, designed to support diverse, underrepresented biotech entrepreneurs who are
LabCentral Launches Second Annual LabCentral Ignite Golden Ticket Contest Read More »
Mission BioCapital to support female entrepreneurs with a $100K Mission BioCapital Award in the 2022 MassNextGen program round March 28, 2022— Today, the Massachusetts Life Sciences Center (MLSC) announced Mission BioCapital as the newest sponsor for the MLSC’s Massachusetts Next Generation Initiative (MassNextGen), a competitive program for women-led life sciences companies. Mission BioCapital is sponsoring
CAMBRIDGE, Mass. & SAN FRANCISCO, December 08, 2021— Mission BioCapital, a venture capital firm focused on making investments in early-stage life sciences companies that it uniquely supports as they grow, announced it has made key additions and promotions to its staff after raising its most recent fund, Mission BioCapital V LP. The firm has hired
Mission BioCapital Boosts Team to Support Investments From New Fund Read More »
